Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals Inc. (AGNPF) Revenue
Annual & quarterly revenue history · segment & region breakdown
AGNPF · revenue · updated Jun 15, 2026
Core revenue metrics
Trailing 12 monthsAlgernon Pharmaceuticals Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2015 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-08-31 | $0.00B | +$0.00B | — |
| 2024-08-31 | $0.00B | +$0.00B | — |
| 2023-08-31 | $0.00B | +$0.00B | — |
| 2022-08-31 | $0.00B | +$0.00B | — |
| 2021-08-31 | $0.00B | +$0.00B | — |
| 2020-08-31 | $0.00B | +$0.00B | — |
| 2019-08-31 | $0.00B | +$0.00B | — |
| 2018-08-31 | $0.00B | +$0.00B | — |
| 2017-08-31 | $0.00B | +$0.00B | — |
| 2016-08-31 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Algernon Pharmaceuticals Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Algernon Pharmaceuticals Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CAD.
Data sourced from Algernon Pharmaceuticals Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
AGNPF revenue · 4 questionsAGNPF's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Algernon Pharmaceuticals Inc. SEC filings · GAAP · Algernon Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 15, 2026